Search

CN-122004825-A - Nasal cavity nursing allergy symptom monitoring system and method

CN122004825ACN 122004825 ACN122004825 ACN 122004825ACN-122004825-A

Abstract

The application provides a nasal cavity nursing allergy symptom monitoring system and method, which are used for extracting characteristic impedance parameters reflecting connection tightness degree among mucous membrane epithelial cells according to electrical impedance spectrum data of nasal cavity mucous membrane surfaces of a user, determining offset of the characteristic impedance parameters relative to personal health state reference values of the user so as to generate quantitative attenuation coefficients of nasal cavity mucous membrane defense functions, determining inhalation doses of the user on allergens in unit time according to real-time allergen concentration data of the environment of the user and preset individual standard respiratory parameters, further determining individual exposure levels of the user according to the quantitative attenuation coefficients and the inhalation doses of the allergens in unit time, and performing risk assessment based on the individual exposure levels and allergen specific IgE detection results of the user so as to generate risk grades of allergy attacks of the user in the environment. By adopting the scheme of the application, the evaluation distortion caused by the difference of the real-time defense functions of the individual can be reduced.

Inventors

  • WU LIHUA

Assignees

  • 福州大学附属省立医院

Dates

Publication Date
20260512
Application Date
20260302

Claims (10)

  1. 1. An allergen exposure risk assessment method for a nasal care allergy symptom monitoring system, the method comprising the steps of: collecting electrical impedance spectrum data of the nasal mucosa surface of a user; extracting characteristic impedance parameters reflecting the connection tightness degree between the epithelial cells of the mucous membrane according to the curve morphological characteristics of the impedance value along with the frequency change in the electrical impedance spectrum data; determining the offset of the characteristic impedance parameter relative to a user personal health state reference value, and further generating a quantized attenuation coefficient of the nasal mucosa defense function; Determining the inhalation dosage of the user to the allergen in unit time according to the real-time allergen concentration data of the environment where the user is located and the preset individual standard respiratory parameter, and further determining the individual exposure level of the user according to the quantitative attenuation coefficient and the inhalation dosage of the user to the allergen in unit time; And performing risk assessment based on the individual exposure level and the allergen specific IgE detection result of the user, so as to generate the risk level of the allergy attack of the user in the environment.
  2. 2. The method according to claim 1, wherein extracting characteristic impedance parameters reflecting the tightness of the connection between the mucosal epithelial cells from the characteristic of the curve morphology of the impedance values with the change of frequency in the electrical impedance spectrum data comprises: Determining a curve morphological characteristic of impedance value along with frequency change from the electrical impedance spectrum data; Analyzing according to the curve morphological characteristics to obtain tissue microstructure attributes of the mucosal epithelial cells; The tissue microstructure attributes are quantified as characteristic impedance parameters reflecting how tightly the mucosal epithelial cells are connected.
  3. 3. The method according to claim 1, wherein determining the offset of the characteristic impedance parameter relative to a reference value of the personal health state of the user, and further generating a quantized attenuation coefficient of the nasal mucosa defense function, comprises: acquiring a historical characteristic impedance parameter sequence of a user in a healthy state; Determining a personal health state reference value of the user through the historical characteristic impedance parameter sequence; determining an offset between the characteristic impedance parameter and the personal health state reference value; and determining a quantized attenuation coefficient of the nasal mucosa defense function according to the offset and a preset mapping table.
  4. 4. The method of claim 1, wherein determining the inhaled dose of the allergen per unit time by the user from real-time allergen concentration data of the environment in which the user is located in combination with preset individual standard respiratory parameters comprises: acquiring real-time allergen concentration data of an environment where a user is located and individual standard breathing parameters of the user; constructing a breathing model for estimating ventilation per unit time based on the individual standard breathing parameters; Determining an inhaled dose of the allergen per unit time for the user by the breathing model and the real-time allergen concentration data.
  5. 5. The method of claim 1, wherein determining the individual exposure level of the user based on the quantified attenuation coefficient and the inhaled dose of allergen per unit time comprises: Correcting the allergen inhalation dosage in unit time through the quantitative attenuation coefficient to obtain an individual effective exposure dosage corrected by the mucosa defense state; And carrying out standardized mapping on the effective exposure dose of the individual and the real-time allergen concentration data of the current environment, and generating the individual exposure level of the user.
  6. 6. The method of claim 1, wherein performing a risk assessment based on the individual exposure level and the allergen-specific IgE detection result of the user, thereby generating a risk level of an allergy attack of the user in the environment comprises: acquiring an allergen-specific IgE detection result of a user; constructing a risk conversion factor of user allergy according to the allergen-specific IgE detection result; generating a risk level of an allergic episode of the user in the environment according to the risk conversion factor in combination with the individual exposure level.
  7. 7. The method of claim 1, wherein the allergen-specific IgE detection result of the user is key immunological index data for diagnosing type I allergy obtained by an in vitro serological detection method.
  8. 8. A nasal care allergy symptom monitoring system comprising an allergen exposure risk assessment unit, wherein the allergen exposure risk assessment unit comprises: the acquisition module is used for acquiring electrical impedance spectrum data of the nasal mucosa surface of the user; The processing module is used for extracting characteristic impedance parameters reflecting the connection tightness degree between the mucous membrane epithelial cells according to the curve morphological characteristics of the impedance value along with the frequency change in the electrical impedance spectrum data; the processing module is also used for determining the offset of the characteristic impedance parameter relative to the personal health state reference value of the user, and further generating a quantized attenuation coefficient of the nasal mucosa defense function; The processing module is further used for determining the inhalation dosage of the user to the allergen in unit time according to the real-time allergen concentration data of the environment where the user is located and the preset individual standard breathing parameters, and further determining the individual exposure level of the user according to the quantitative attenuation coefficient and the inhalation dosage of the user to the allergen in unit time; and the execution module is used for carrying out risk assessment based on the individual exposure level and the allergen specific IgE detection result of the user, so as to generate the risk level of the allergy attack of the user in the environment.
  9. 9. A computer device comprising a memory and a processor, the memory storing a computer program, characterized in that the processor, when executing the computer program, implements the steps of the allergen exposure risk assessment method of any one of claims 1 to 7.
  10. 10. A computer readable storage medium storing a computer program, characterized in that the computer program when executed by a processor implements the steps of the allergen exposure risk assessment method according to any one of claims 1 to 7.

Description

Nasal cavity nursing allergy symptom monitoring system and method Technical Field The application relates to the technical field of allergy symptom monitoring, in particular to a nasal cavity nursing allergy symptom monitoring system and method. Background The allergic symptom monitoring refers to a technology for converting scattered and subjective physiological responses generated by a human body under specific allergen stimulation into a standardized health data model with time sequence rule, intensity grading and triggering relevance through a series of systematic observation and analysis processes such as multidimensional sign record, environment and exposure factor correlation analysis and the like. The nasal cavity nursing allergy symptom monitoring refers to a process of converting subjective discomfort and objective pathological manifestation of a nasal cavity of an individual into a structured health track model with characteristics related to temporal-spatial dynamics, nursing responsiveness and trigger factors through a series of integrated observation and analysis processes of nasal cavity local sign data acquisition, multisource information synchronous recording and the like, wherein the nasal cavity nursing allergy symptom monitoring is often based on the evaluation of allergen exposure risk of a user, in the traditional allergic rhinitis allergen exposure risk evaluation method, the simple combination of multi-dependence environmental concentration monitoring and static personal allergy history is difficult to dynamically quantify the real-time physiological defense barrier state of the nasal mucosa of the individual, so that the individual accuracy and timeliness of risk evaluation have obvious deviation, for example, the traditional method can give the same risk level when evaluating users with the same concentration of two environmental pollens and similar serum-specific IgE levels, however, one user can possibly cause the nasal cavity epithelial cell connection integrity to be damaged, the defense function to be in a temporary attenuation state due to upper respiratory tract infection, the biological stimulation intensity generated by the same physical allergen inhalation dose is more than the clinical-induced biological stimulation intensity, and clinical biological stimulation is higher than that of the clinical stimulation is caused by the other user, and thus the physiological stimulus is more difficult to evaluate the physiological risk of the mucosa, and the physiological stimulus is more difficult than the problem of the user is caused by the real-time risk of the situation. Disclosure of Invention The application provides a nasal cavity nursing allergy symptom monitoring system and a nasal cavity nursing allergy symptom monitoring method, which can reduce evaluation distortion caused by real-time defense function difference of an individual. In a first aspect, the present application provides a method of allergen exposure risk assessment for use in a nasal care allergy symptom monitoring system, the method comprising the steps of: collecting electrical impedance spectrum data of the nasal mucosa surface of a user; extracting characteristic impedance parameters reflecting the connection tightness degree between the epithelial cells of the mucous membrane according to the curve morphological characteristics of the impedance value along with the frequency change in the electrical impedance spectrum data; determining the offset of the characteristic impedance parameter relative to a user personal health state reference value, and further generating a quantized attenuation coefficient of the nasal mucosa defense function; Determining the inhalation dosage of the user to the allergen in unit time according to the real-time allergen concentration data of the environment where the user is located and the preset individual standard respiratory parameter, and further determining the individual exposure level of the user according to the quantitative attenuation coefficient and the inhalation dosage of the user to the allergen in unit time; And performing risk assessment based on the individual exposure level and the allergen specific IgE detection result of the user, so as to generate the risk level of the allergy attack of the user in the environment. In some embodiments, extracting the characteristic impedance parameter reflecting the connection tightness degree between the mucous membrane epithelial cells according to the curve morphological characteristics of the impedance value changing along with the frequency in the electrical impedance spectrum data specifically comprises: Determining a curve morphological characteristic of impedance value along with frequency change from the electrical impedance spectrum data; Analyzing according to the curve morphological characteristics to obtain tissue microstructure attributes of the mucosal epithelial cells; The tissue microstructure attribut